St Jude Medical reports positive CardioMEMS HF trial data

St Jude Medical has announced the findings of a retrospective data analysis that further highlights the practical benefits offered by its CardioMEMS HF system.

This new study of data from the Champion clinical trial highlighted a significant reduction in 30-day hospital readmission rates for patients age 65 and older when treated with the pulmonary artery pressure monitoring device.

All of the patients had been hospitalised for heart failure in the previous 12 months, but St Jude Medical's system was able to cut all-cause 30-day readmissions by 58 percent and heart failure readmissions by 78 percent.

CardioMEMS uses a miniaturised wireless monitoring sensor implanted in the pulmonary artery via a minimally invasive procedure to directly measure arterial pressure, making it easier for clinicians to provide proactive treatment.

Dr Mark Carlson, chief medical officer for St Jude Medical, said: "We continue our commitment of investing in meaningful clinical research with this new data analysis from the Champion trial that is helping shape the way physicians are caring for their patients."

The company achieved year-on-year growth of three percent during the third quarter of 2014, with US Medicaid approval for CardioMEMS HF highlighted as a key milestone during this period.